Breaks Categories: News

TuesdayNov 15, 2022 2:20 pm

NetworkNewsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) ‘Strikingly Different’ EV Crossover Tour Takes the Spotlight in Vegas, Heads to Texas

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has successfully completed the third stop of the Mullen FIVE Strikingly Different EV Crossover Tour in Las Vegas, Nevada. According to the announcement, Mullen continues onwards to Texas, with stops this week in Dallas and Houston. The Mullen FIVE EV vehicle on tour is equipped with a completely updated infotainment system that features PERSONA, Mullen’s proprietary Personal Vehicle Assistant (“PVA”), which utilizes facial recognition technology to provide every driver with a highly individualized experience. “This tour not only allows the public to see what Mullen has…

Continue Reading

TuesdayNov 15, 2022 2:06 pm

NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has scheduled its Annual Meeting of Stockholders; the meeting is slated for Jan. 12, 2023. According to the announcement, any proposals to be considered for the meeting should be sent to the company’s principal executive offices in Las Vegas; all proposals must comply with the procedures for stockholder proposals in the company's bylaws and need to be received by the close of business on Nov. 25, 2022. The company will file the official Notice of Annual Meeting and Proxy Statement…

Continue Reading

TuesdayNov 15, 2022 1:54 pm

NetworkNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and provided a corporate update. “Initial, preliminary data from our second patient dosed with CycloSam continues to show positive signals in terms of safety and efficacy. While it is too early for formal conclusions to be made of these results, CycloSam generally performed how we expected it to perform, even given the lowest dosage in our dose-escalating study. This is all very encouraging,” said Douglas R.…

Continue Reading

TuesdayNov 15, 2022 1:40 pm

NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Congratulates Dirk Görlich on $1.4M World Laureates Association Prize in Life Sciences

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today congratulated its co-lead scientific research collaborator Professor Dr. Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences (“MPI”), on being awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his seminal work describing protein transport within the cell. “On behalf of BiondVax’s team, I wish to offer my sincere congratulations to Dirk on being awarded the inaugural WLA Prize in Life Sciences. The…

Continue Reading

TuesdayNov 15, 2022 1:26 pm

NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug Drysdale. “In addition to our clinical work, we have been actively broadening our robust IP portfolio through securing strategic licensing agreements for preclinical psychedelic-based compounds that will support our ongoing drug development efforts. These recent…

Continue Reading

TuesdayNov 15, 2022 12:56 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Multimillion-Dollar Claim Has Been Dismissed

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that a $30.2 million claim against the company has been dismissed. The claim was filed against the company by its former CEO, Dr. Raza Bokhari. In the claim, Bokhari asserted that he had been wrongfully dismissed from his position at FSD Pharma. An arbitrator evaluated the claim and ruled that it should be dismissed. In addition, Bokhari was ordered by the arbitrator to pay a certain amount to FSD Pharma…

Continue Reading

TuesdayNov 15, 2022 11:54 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced its Q3 2022 financial report; the company also provided an update regarding its anticancer drug candidates. The report noted that significant progress has been made in CNSP’s key trial designed to study Berubicin’s efficacy in the treatment of recurrent glioblastoma multiforme (“GBM”); that progress includes multiple clinical trial sites being approved for enrollment along with 29 of 68 clinical sites in the United States and Europe already enrolling patients. The company anticipates…

Continue Reading

MondayNov 14, 2022 3:35 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Finalized Deal to Provide 40-Plus Machines to NJ University

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), continues to sign contracts and agreements as it delivers on its mission to provide safety and security to a growing number of organizations around the country. Most recently, Knightscope has signed a contract with a New Jersey university to deliver 31 K1 Blue Light Towers and 10 K1 Blue Light E-Phones. The new contract shows the rising interest that college campuses are showing in Knightscope services. According to the announcement, college safety is a major priority for students when they select which institution to attend. Consequently, colleges and universities…

Continue Reading

MondayNov 14, 2022 3:22 pm

NetworkNewsBreaks – Canaan Inc. (NASDAQ: CAN) Releases Q3 2022 Financial Report

Canaan (NASDAQ: CAN), a leading high-performance computing solutions provider, is reporting its unaudited financial and operating results for the three-month period ended Sept. 30, 2022. Numbers of note from the report include computing power sold during the quarter totaling 3.5 million Thash/s, a 37.1% decrease from Q2 2022 and a 48.5% from 6.7 million Thash/s in the same period of 2021. CAN revenues reached $137.5 million, a decrease of 40.8% from the second quarter 2022 and a 25.8% decrease from the same period in 2021, with gross profit coming in at$32.9 million, net income totaling $8.6 million, and non-GAAP adjusted net reaching  $23.4 million.…

Continue Reading

MondayNov 14, 2022 3:12 pm

NetworkNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Announces Strategic Move to Sell Alta Mesa Project, Focus on Uranium and Rare Earth Production

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium and rare earth elements (“REE”), today announced its entry into a definitive agreement to sell three wholly owned subsidiaries that together hold its Alta Mesa ISR Project to enCore Energy for total consideration of $120 million (the “transaction”). The transaction, which is expected to close by the end of 2022 or early 2023, is significant for the company, as the cash received is expected to fully finance much of Energy Fuels’ uranium, REE, vanadium and medical isotope business plans for the next two to three years without…

Continue Reading